Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Journal of the European Academy of Dermatology and Venereology : JEADV|September 20, 2019
Follicular occlusion tetrad in a male patient with pachyonychia congenita: clinical and genetic analysisM L Musumeci, F Fiorentini, L Bianchi, et al.
Analytical and Bioanalytical Chemistry|July 2, 2023
Novel bionanomaterial based on Spirulina maxima algae and graphene oxide for lead microextraction and determination in water and infant beveragesEstefanía B Ingrassia, Emiliano F Fiorentini, Rodolfo G Wuilloud, et al.
La Radiologia Medica|June 1, 1997
[Computerized tomography-guided neurolytic block of the splanchnic nerve]M Cariati, F Henriquet, F Fiorentini, et al.
Journal of Medicinal Chemistry|January 7, 1994
Mixed 5-HT1A/D-2 activity of a new model of arylpiperazines: 1-aryl-4-[3-(1,2-dihydronaphthalen-4-yl)-n-propyl]piperazines. 1. Synthesis and structure-activity relationshipsR Perrone, F Berardi, N A Colabufo, et al.
European Journal of Cancer (Oxford, England : 1990)|October 27, 2009
Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approachM Rocchetti, F Del Bene, M Germani, et al.
Journal of Medicinal Chemistry|March 17, 1995
High affinity and selectivity on 5-HT1A receptor of 1-aryl-4-[1-tetralin)alkyl]piperazines. 2R Perrone, F Berardi, N A Colabufo, et al.
Journal of Neural Transmission. Supplementum|January 1, 1995
Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegilineP Dostert, M Strolin Benedetti, S Persiani, et al.
British Journal of Clinical Pharmacology|December 1, 1996
Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humansY Böttiger, P Dostert, M S Benedetti, et al.
Journal of Clinical Pharmacology|May 12, 2000
Pharmacokinetics of single-dose reboxetine in volunteers with renal insufficiencyF Coulomb, F Ducret, J P Laneury, et al.
Journal of Chemotherapy (Florence, Italy)|October 1, 1995
Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitisM Cazzola, A Vinciguerra, G F Beghi, et al.
Pageof 4